351
Participants
Start Date
February 14, 2019
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2028
Doxorubicin
A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
Ifosfamide or dacarbazine
A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
Doxorubicin
A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
Ifosfamide or dacarbazine
A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
At the discretion of the investigator
Drug at the discretion of the investigator.
RECRUITING
Institut Paoli Calmettes, Marseille
RECRUITING
Centre Georges François Leclerc, Dijon
RECRUITING
Institut Claudius Regaud, Toulouse
RECRUITING
Institut Bergonie, Bordeaux
RECRUITING
Insitut du Cancer, Montpellier
RECRUITING
Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain
RECRUITING
CHRU Strasbourg, Strasbourg
RECRUITING
Centre Léon Bérard, Lyon
RECRUITING
CHU Dupuytren, Limoges
NOT_YET_RECRUITING
Institut Gustave Roussy, Villejuif
Lead Sponsor
Collaborators (2)
Novartis
INDUSTRY
Chugai Pharma France
INDUSTRY
Institut Bergonié
OTHER